Investors

Webcast ImageWebcast
Rodman & Renshaw 18th Annual Global Investment Conference  (Live)
09/13/16 at 12:00 p.m. ET
Rodman & Renshaw 18th Annual Global Investment Conference
Tuesday, September 13, 2016  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
Corporate Profile
Proteon Therapeutics is a biopharmaceutical company developing vonapanitase (formerly PRT-201), an investigational drug to improve arteriovenous fistula (AVF) patency, the period of time during which an AVF remains open with adequate blood flow to enable hemodialysis. Vonapanitase is being evaluated in two Phase 3 clinical trials, and data from the first Phase 3 clinical trial are anticipated in the first quarter of 2017. Vonapanitase may have multiple surgical and endovascular applications in which vessel injury leads to blockages in blood vessels and reduced blood flow, and is also currently being investigated as a potential treatment for patients with symptomatic peripheral artery disease (PAD). The company is headquartered in Waltham, MA.
Stock Quote
PRTO (Common Stock)
ExchangeNASDAQ GS (US Dollar)
Price$9.72
Change (%) Stock is Down 0.16 (1.62%)
Volume4,693
Data as of 08/30/16 4:00 p.m. ET
Refresh quote
Recent Press ReleasesMore >>
DateTitle 
08/08/16Proteon Therapeutics Announces Second Quarter 2016 Financial ResultsPrinter Friendly Version
06/15/16Proteon Therapeutics to Present at the JMP Securities Life Sciences Conference June 22ndPrinter Friendly Version
05/09/16Proteon Therapeutics Announces First Quarter 2016 Financial ResultsPrinter Friendly Version
04/28/16Proteon Therapeutics Announces Survey Findings Demonstrating Impact of Vascular Access Failure on Hemodialysis PatientsPrinter Friendly Version
Upcoming EventsMore >>
DateTitle
09/08/16
Baird 2016 Healthcare Conference
09/13/16
Rodman & Renshaw 18th Annual Global Investment Conference
11/29/16
Oppenheimer Life Science Summit
Print Page Print Page
E-mail Page E-mail Page
RSS Feeds RSS Feeds
E-mail Alerts E-mail Alerts
Financial Tear Sheet Financial Tear Sheet

IR Contact

George Eldridge
781-890-0102 x1026
geldridge@proteontherapeutics.com

Media Contact

Daniel Gottlieb
781-890-0102 x1025
dgottlieb@proteontherapeutics.com